Clinical Trials Directory

Trials / Conditions / Unknown Primary Tumors

Unknown Primary Tumors

12 registered clinical trials studyying Unknown Primary Tumors — 4 currently recruiting.

StatusTrialSponsorPhase
RecruitingStudy of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and In
NCT07524114
University Health Network, Toronto—
RecruitingPaCIFiC-CUP Classifies Cancer of Unknown Primary
NCT06140992
Sun Yat-sen University—
UnknownReal-time Targeted Fluorescence Endoscopy for Detection of the Primary Cancer Lesion in Patients With a Metast
NCT06100081
University Medical Center GroningenN/A
RecruitingSolving Riddles Through Sequencing
NCT05046444
Munich Leukemia Laboratory—
CompletedThe Registry of Oncology Outcomes Associated With Testing and Treatment
NCT04028479
Taproot Health—
RecruitingInvestigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
NCT04273061
British Columbia Cancer AgencyPhase 2
WithdrawnPhase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Prima
NCT04276597
Excel Diagnostics and Nuclear Oncology CenterPhase 2
CompletedHARE-40: HPV Anti-CD40 RNA vaccinE
NCT03418480
University of SouthamptonPhase 1 / Phase 2
CompletedA Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)
NCT02607202
Fondazione del Piemonte per l'OncologiaPhase 2
WithdrawnCisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor
NCT00458315
Rigshospitalet, DenmarkPhase 2
TerminatedCapecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown P
NCT00201734
Ohio State University Comprehensive Cancer CenterPhase 1 / Phase 2
Approved For MarketingEarly Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusio
NCT04100694
Merus B.V.—